Insider · CIK 0001355416
David W Carey
director
Files at DRS (Leonardo DRS, Inc.). First filing Jun 16, 2025, latest Jun 16, 2025.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 1
$0 bought, $296k sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
DRS: Leonardo DRS, Inc.
DRSOct 9, 2026 · close 36.24
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 34Weak | DRSsell Leonardo DRS, Inc. | $296k 6,438 shares | -21% | +73% from low0% from high |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 13, 2025 | DRS Leonardo DRS, Inc. | SOpen-market sale Common Stock | -6,438 | $45.94 | $296k | 23,882 | Jun 16, 2025 |
| Jun 4, 2025 | DRS Leonardo DRS, Inc. | AGrant or award Restricted Stock Unitderivative | +3,556 | $0.00 | $0 | 3,556 | Jun 5, 2025 |
| May 15, 2025 | DRS Leonardo DRS, Inc. | MOption exercise Common Stock | +6,438 | $0.00 | $0 | 30,320 | May 16, 2025 |
| May 15, 2025 | DRS Leonardo DRS, Inc. | MOption exercise Restricted Stock Unitderivative | -6,438 | $0.00 | $0 | 0 | May 16, 2025 |
| Nov 29, 2024 | DRS Leonardo DRS, Inc. | MOption exercise Common Stock | +3,572 | $0.00 | $0 | 23,882 | Dec 3, 2024 |
| Nov 29, 2024 | DRS Leonardo DRS, Inc. | MOption exercise Restricted Stock Unitderivative | -3,572 | $0.00 | $0 | 0 | Dec 3, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.